To include your compound in the COVID-19 Resource Center, submit it here.

QLT ends Phase III NSCLC trials

QLT (TSE:QLT; QLTI) discontinued the two Phase III trials of tariquidar in combination with first-line chemotherapy for non-small cell lung cancer (NSCLC). The decision followed a recommendation

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE